

■ TEL. : 022 - 3001 5666 ■ FAX : 022 - 2405 7708

E-Mail : info@naxparlab.comVisit us at: www.naxparlab.com

■ CIN No. : L36912MH1982PLC027925

Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX, SION-CHUNABHATTI, MUMBAI - 400 022. INDIA

Date: 13.02.2019

To,
Department of Corporate Service (DCS-CRD), **BSE Limited**Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001

Sub: <u>Submission of Un-Audited Standalone & Consolidated Financial Results for quarter ended</u> 31st December. 2018 in pursuance of Regulation 33 of Listing Obligation and Disclosure Requirement, 2015.

Ref.: Parnax Lab Limited Script Code- 506128

Dear Sir,

Kindly find enclosed herewith the following:

1. A Copy of Standalone & Consolidated Un-Audited Financial results with Limited Review Report of the Company for the quarter ended 31st December, 2018.

Kindly take on record.

Thanking You,

Yours faithfully,

For PARNAX LAB LIMITED

Bhoomi Thakkar

Company Secretary & Compliance Officer

Mumbai

Encl: As above

LADHA SINGHAL & ASSOCIATES

CHARTERED ACCOUNTANTS

To
The Board of Directors,
Parnax Lab Limited,
114, Building No. 8,
Jogani Industrial Complex,
Chunabhatti, Mumbai – 400 022

- 1. We have reviewed the unaudited standalone financial results of **Parnax Lab Limited** ("the company") for the quarter and nine months ended 31st December, 2018 which are included in the accompanying "Statement of Unaudited Standalone Financial Result for the quarter and nine months ended 31st December, 2018" togather with the relevant notes thereon ("the Statement"). The Statement has been prepared by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. The Statement is the responsibility of the company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principal laid down in Indian Accounting Standard for Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
- 2. We conducted our review in accordance with the standards on Review Engagement (SRE) 2410 'Review on Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than as audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principals generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Discloser Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ladha Singhal and Associates

Chartered Accountants (FRN: 120241W)

(Vinod Ladha)

Partner

M. No.: 104151 Place: Mumbai

Dated: 13th February, 2019

CHARTENED

PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.

Tel: 022 - 3001 5666, Fax: 2405 7708, Email: info@naxparlab.com, Website: www.naxparlab.com

CIN:-L36912MH1982PLC027925

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2018

(Rs. in Lakhs)

_	On Naviona	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
S. No.	Particulars	Current Quarter Ended 31.12.2018	Previous Quarter ended 30.09.2018	Correspondi ng Quarter Ended 31.12.2017	Current Nine Months Ended 31.12.2018	Corresponding Nine Months Ended 31.12.2017	Year Ended 31.03.2018
	Revenue from Operations	122.66	196.51	182.02	491.78	423.01	580.31
1	Other Income	13.93	19.66	4.82	38.75	8.74	34.83
111	Total Revenue (I+II)	136.59	216.17	186.84	530.53	431.75	615.14
IV	Expenses						
IV	a) Cost of Material Consumed	40.45	78.25	86.92	178.41	144.02	207.00
	b) Purchase of Stock in trade	8,66	23.30	-	61.08	42.26	64.89
	c) Changes in inventories of finished goods, Work in progress and stock in trade		-	(11.27)	-	(11.27)	
_		13.58	11,19	14.55	34.71	76.38	88.94
	d) Employee benefit expenses	27.44	25.41	26.44	80.99	93.47	129.73
	e) Finance Cost	1.22	1.18	12.04	3.65	36.00	44.11
	f) Depreciation and amortisation expenses	72.25	78.09	47.03	211.46	135.20	204.73
	g) Other expenses	12.20				-	123.40
	h) Impairment of assets classified as held for disposal	163.60	217.42	175.71	570.30	516.06	862.80
	Total Expenses (IV)						10.45.00)
V	Profit/(loss) before exceptional items and tax (III-IV)	(27.01)	(1.25)	11.13	(39.77)	(84.31)	(247.66)
VI	Exceptional Items			-	-		(2.17.00)
VII	Profit/(loss) Before Tax (V-Vi)	(27.01)	(1.25	11.13	(39.77)	(84.31)	(247.66)
VIII	Tax expense						
V ,	a) Current Tax			-	•		47.00)
	b) Deferred Tax				-		(7.66)
	c) Short(Excess) Prov for Tax for Earlier Years						0.02
IX	Profit (Loss) for the period (VII-VIII)	(27.01)	(1.25) 11.13	(39.77	(84.31)	(240.02)
X	Other Comprehensive Income						2.00
~	A. (i) Items that will not be reclassified to profit or loss		-	-			0.29
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-		-
	B. (i) Items that will be reclassified to profit or loss			-			-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-		-		-
XI	Total Other Comprehensive Income for the period					-	0.29
	Total Comprehensive Income comprising profit & other comprehensive						(239.73)
XII	income for the period (VIII+IX) Paid-up equity share capital (Face Value of the share Rs. 10)	850.49	850.49	850.49	850.49	850.49	850.49
XIII	Paid-up equity share capital (Face value of the share Ks. 10)	030.43					
XIV	Earning per equity share (Not Annualised)	(0.32)	(0.01	0.13	(0.47	(0.99) (2.82
	(1) Basic	(0.32)				/	
	(2) Diluted	10.32	(0.01	/1 0.10	10.41	11 13:00	

Notes

1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 13, 2019

2 The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter and nine months ended December 31, 2018

3 EPS for quarter ended is on non annualised basis.

4 The Company is dealing into one segment : Dealing in Pharmaceutical Formulations

5 Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.

By Order of the Board For Parnax Lab Limited

Prakash M Shah Whole Time Director & CEO DIN NO: 00440980

Mumbai

Place: Mumbai Date: 13-02-2019

LADHA SINGHAL & ASSOCIATES

CHARTERED ACCOUNTANTS

To
The Board of Directors,
Parnax Lab Limited,
114, Building No. 8,
Jogani Industrial Complex,
Chunabhatti, Mumbai – 400 022

- We have reviewed the unaudited consolidated financial results of **Parnax Lab Limited** ("the Parent") and its Subsidiary, Naxpar Pharma Private Limited ("the Subsidiary"), for the quarter and nine month ended December 31, 2018 which are included in the accompanying "Statement of Unaudited Consolidated Financial Results for the quarter and nine month ended December 31, 2018" together with the relevant notes thereon ("the Statement'). The Statement has been prepared by the Parent pursuant to Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015") read with SEBI Circular No. CIR/CFD/FAC/62/2016dated July 05, 2016. The Statement is the responsibility of the Parent's Management and has been approved by the Board of Directors. The Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies. Our responsibility is to issue a report on the Statement based on our review.
- (ii) We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Parent's personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
- (iii) Based on our review conducted as stated above, nothing has come to our attention that cause us to believe that the accompanying Statement, prepared in accordance with the aforesaid Ind AS and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ladha Singhal and Associates

Chartered Accountants

(FRN: 120241W)

(Vinod Ladha)
Partner

M. No. 104151 Place: Mumbai

Dated: 13th February, 2019

PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022. Tel: 022 - 3001 5666, Fax: 2405 7708, Email: info@naxparlab.com, Website: www.naxparlab.com CIN:-L36912MH1982PLC027925

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31.12.2018

S.	Particulars	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	(Rs. in Lakhs Audited
No.		Current Quarter Ended 31.12.2018	Previous Quarter ended 30.09.2018	Correspondin g Quarter Ended 31.12.2017	Current Nine Months Ended 31.12.2018	Correspondin	Current Year Ended 31.03.2018
	Revenue from Operations	2,331.21	4,226.84	2,509.84	8,864,45	8,384.06	10,549.86
1	Other Income	52.78	84.16	5.27	143.29	36.07	134.28
#1	Total Revenue (I+II)	2,383.99	4,311.00	2,515.11	9,007.74	8,420.13	10,684.14
V	Expenses					0,120.10	10,004.14
	a) Cost of Material Consumed	1.086.46	1,135.94	1,298.20	3,379.26	4,526.43	5,443.93
	b) Purchase of Stock in trade	84.44	729.16	1,200.20	856.01	30.90	70.09
	c) Changes in inventories of finished goods, Work in progress and stock in trade	(1.85)	107.46	(9.33)	35.63	(119.71)	(24.34)
	d) Employee benefits expenses	338,34	372.29	306.77	1.008.56	845.09	1,167.84
	e) Finance Cost	104.04	87.32	118.99	283.16	336.07	434.50
	Depreciation and amortisation expenses	94.26	96.34	95.77	277.92	277.58	374.02
	g) Other expenses	634.63	1,366.29	642.37	2,635.25	2.154.70	2,792.49
	h) Impairment of assets classified as held for disposal	-	1,000.20	042.07	2,035.25	2,154.70	123.40
	Total Expenses (IV)	2,340.32	3,894.80	2,452.77	8,475,79	8,051.06	10,381.93
/	Profit/(loss) before exceptional items and tax (III-IV)	43.67	416.20	62.34	531.95	369.07	302.21
/1	Exceptional Items			02.04	331.33	303.07	302.21
/11	Profit/(loss) Before Tax (V-VI)	43.67	416.20	62.34	531.95	369.07	302.21
/111	Tax expense			02.04	331.33	303.07	302.21
	a) Current Tax						150.00
	b) Deferred Tax			•	-	-	48.08
	c) Short (Excess) Prov for Tax for Earlier Years	4.71		(1.46)	4.71	(0.40)	(1.47)
<u> </u>	Profit/ (Loss) for the period (VII-VIII)	38.96	416.20	63.80	527.24	(1.46) 370.53	105.60
	Minority Interest Profit (Loss)	0.13	0.80	0.11	1.13	0.91	0.20
(I	Profit/(Loss) After Share of Profit (Loss) of minority interest	38.83	415.40	63.69	526.11	369.62	105.40
(H	Other Comprehensive Income	00.00	410.40	03.03	320.11	303.62	105.40
	A. (i) Items that will not be reclassified to profit or loss						0.70
	(ii) Income tax relating to items that will not be reclassified to profit or loss						2.70
	B. (i) Items that will be reclassified to profit or loss						-
	(ii) Income tax relating to items that will be reclassified to profit or loss						•
XIII	Total Other Comprehensive Income for the period			, .		•	2.70
XIV	Total Comprehensive Income comprising profit and other comprehensive income for the period (IX+XIII)	38.83	415.40	63.80	527.24	370.53	108.30
YV	Total modifile on South and the state of the						
XV	Total profit/(loss) for the year attributable to: - Owners of the Company						
	- Non-controlling interests	38.83	415.40	63.69	526.11	369.62	105.60
		0.13	0.80	0.11	1.13-	0.91	0.20
XVI	Other Comprehensive income attributable to :					19.3	
	- Owners of the Company				100	1181	0.00
	- Non-controlling interests				11 7/4		2.69
						umbai a	0.01
VVVII	Total Comprehensive income attributable to:				11	47 / 12 ///	

- Owners of the Company	38.83	415.40	63.69	526.11	369.62	108.29
- Non-controlling interests	0.13	0.80	0.11	1.13	0.91	0.20
VIII Paid-up equity share capital (Face Value of the share Rs. 10) IX Earning per equity share (Not Annualised)	850.49	850.49	850.49	850.49	850.49	850.49
(1) Basic	0.40					
(2) Diluted	0.46	4.89	0.75	6.20	4.36	1.24
Notes	0.46	4.89	0.75	6.20	4.36	1.24

The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 13, 2019

2 The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter and nine months ended December 31, 2018

EPS for quarter ended is on non annualised basis.

4 The Company is dealing into one segment : Dealing in Pharmaceutical Formulations

5 Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.

Place: Mumbai Date: 13-02-2019

By Order of the Board For Parnax Lab Limited

> Prakash M Shah Whole Time Director & CEO DIN NO: 00440980